Despite the availability of effective anti-emetics, some patients may still experience breakthrough nausea and vomiting. This can occur due to individual variations in metabolism, the emetogenic potential of the chemotherapy regimen, or other underlying health conditions. Combining different classes of anti-emetics, known as a multi-modal approach, can help address these challenges.